etherna Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 89

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $34.1M

etherna General Information

Description

Developer of precision therapeutics intended to develop next-generation targeted therapies through proprietary single-domain antibody and drug conjugate platforms. The company specializes in developing next-generation products with antibody engineering, target identification, drug conjugate development, preclinical research, and R&D collaborations, enabling biopharmaceutical partners to develop targeted therapeutic candidates and advance drug development programs.

Contact Information

Website
www.etherna.be
Formerly Known As
eTheRNA Immunotherapies
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Galileilaan 19
  • 2845 Niel
  • Belgium
+32 03
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Corporate Office
  • Galileilaan 19
  • 2845 Niel
  • Belgium
+32 03

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

etherna Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 12-Oct-2026 $34.1M Completed Generating Revenue
7. Later Stage VC (Series B2) 23-Aug-2022 Completed Generating Revenue
6. Later Stage VC (Series B) 16-Jun-2020 Completed Generating Revenue
5. Later Stage VC 25-Jul-2019 Completed Generating Revenue
4. Later Stage VC (Series A) 05-Jul-2018 Completed Generating Revenue
3. Grant 25-Sep-2017 Completed Generating Revenue
2. Accelerator/Incubator 05-Jan-2017 Completed Generating Revenue
1. University Spin-Out 01-Jan-2013 Completed Startup
To view etherna’s complete valuation and funding history, request access »

etherna Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference B2
Preference B2
Preference B2
Class B
Class B
Class B
Class B
Preference A
Preference 4,592 $2.45 $2.45 1x $2.45 0.31%
Preference 22,733 $1.43 $1.43 1x $1.43 1.54%
To view etherna’s complete cap table history, request access »

etherna Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision therapeutics intended to develop next-generation targeted therapies through proprietary single-do
Biotechnology
Niel, Belgium
89 As of 2026

Abingdon, United Kingdom
 

Berlin, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

etherna Competitors (32)

One of etherna’s 32 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
TME Pharma Formerly VC-backed Berlin, Germany
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Transgene Corporation Illkirch-Graffenstaden, France
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 32 competitors. Get the full list »

etherna Patents

etherna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026171886-A1 Mrna combination for use in preventing and/or treating an autoimmune disease Pending 13-Feb-2025
WO-2026093528-A1 A purification of rna by flowthrough chromatography Pending 31-Oct-2024
WO-2026047192-A1 Ionizable lipids Pending 30-Aug-2024
WO-2026008584-A1 Stabilizing lipids Pending 01-Jul-2024
AU-2024403484-A1 Lipid nanoparticles Pending 22-Dec-2023 A61K9/0019
To view etherna’s complete patent history, request access »

etherna Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

etherna Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
BNP Paribas Fortis Private Equity Growth/Expansion Minority
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Fund+ Venture Capital Minority
Grand Decade Corporation Minority
You’re viewing 5 of 14 investors. Get the full list »

etherna Investments (2)

etherna’s most recent deal was a Early Stage VC with Traianus Partners. The deal was made on 28-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Traianus Partners 28-Mar-2024 Early Stage VC Other Financial Services
AuroRNA Biotech 25-Nov-2020 Joint Venture Biotechnology
To view etherna’s complete investments history, request access »

etherna FAQs

  • When was etherna founded?

    etherna was founded in 2013.

  • Where is etherna headquartered?

    etherna is headquartered in Niel, Belgium.

  • What is the size of etherna?

    etherna has 89 total employees.

  • What industry is etherna in?

    etherna’s primary industry is Biotechnology.

  • Is etherna a private or public company?

    etherna is a Private company.

  • What is the current valuation of etherna?

    The current valuation of etherna is .

  • What is etherna’s current revenue?

    The current revenue for etherna is .

  • How much funding has etherna raised over time?

    etherna has raised $122M.

  • Who are etherna’s investors?

    BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, EQT Life Sciences, Fund+, and Grand Decade are 5 of 14 investors who have invested in etherna.

  • Who are etherna’s competitors?

    Adaptimmune Therapeutics, TME Pharma, WaVe Life Sciences, Transgene, and Immunocore Holdings are some of the 32 competitors of etherna.

  • When was etherna acquired?

    etherna was acquired on 12-Oct-2026.

  • Who acquired etherna?

    etherna was acquired by Valerio Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process